- Home
- WSBF vs MDWD Comparison
WSBF vs MDWD Comparison
Compare WSBF & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSBF
- MDWD
- Stock Information
- Founded
- WSBF 1921
- MDWD 2000
- Country
- WSBF United States
- MDWD Israel
- Employees
- WSBF N/A
- MDWD N/A
- Industry
- WSBF Savings Institutions
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- WSBF Finance
- MDWD Health Care
- Exchange
- WSBF Nasdaq
- MDWD Nasdaq
- Market Cap
- WSBF 288.1M
- MDWD 235.7M
- IPO Year
- WSBF N/A
- MDWD 2014
- Fundamental
- Price
- WSBF $15.78
- MDWD $18.00
- Analyst Decision
- WSBF
- MDWD Strong Buy
- Analyst Count
- WSBF 0
- MDWD 2
- Target Price
- WSBF N/A
- MDWD $37.50
- AVG Volume (30 Days)
- WSBF 41.6K
- MDWD 67.3K
- Earning Date
- WSBF 10-23-2025
- MDWD 11-20-2025
- Dividend Yield
- WSBF 3.81%
- MDWD N/A
- EPS Growth
- WSBF 87.32
- MDWD N/A
- EPS
- WSBF 1.32
- MDWD N/A
- Revenue
- WSBF $137,060,000.00
- MDWD $20,932,000.00
- Revenue This Year
- WSBF N/A
- MDWD $21.39
- Revenue Next Year
- WSBF N/A
- MDWD $23.01
- P/E Ratio
- WSBF $11.91
- MDWD N/A
- Revenue Growth
- WSBF 2.87
- MDWD 6.15
- 52 Week Low
- WSBF $11.61
- MDWD $14.14
- 52 Week High
- WSBF $16.75
- MDWD $22.51
- Technical
- Relative Strength Index (RSI)
- WSBF 59.58
- MDWD 49.48
- Support Level
- WSBF $15.11
- MDWD $16.66
- Resistance Level
- WSBF $15.98
- MDWD $18.62
- Average True Range (ATR)
- WSBF 0.29
- MDWD 0.70
- MACD
- WSBF 0.03
- MDWD -0.02
- Stochastic Oscillator
- WSBF 73.56
- MDWD 59.56
About WSBF Waterstone Financial Inc. (MD)
Waterstone Financial Inc is a holding company. Through its subsidiaries, it operates in two reportable segments: Community Banking and Mortgage Banking. The Community Banking segment provides consumer and business banking products and services to customers, which include various types of loans, deposits, and personal investment services. The Mortgage Banking segment involves residential mortgage loans for the primary purpose of sale in the secondary market. The vast majority of its revenue comes from the Community Banking segment.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.